Dividend Information About Merck: Everything You Need to Know Before Its Ex-Dividend Date on Sep 15, 2025

Merck & Co. (MRK) has announced a cash dividend of $0.81000000 per share, with an ex-dividend date set for Sep 15, 2025. The dividend was officially declared on Jul 22, 2025, and will be distributed to eligible shareholders on Oct 7, 2025. This payment represents an increase compared to the average of the last 10 dividends, which stood at approximately $0.4905 per share. The most recent dividend was also paid on Jul 8, 2025, with the same amount of $0.81000000 per share. The consistent use of cash dividends indicates the company’s ongoing commitment to returning value to shareholders, even as it navigates a complex business environment.

Over the past week, Merck has been at the center of several key developments that could influence its market performance. Most notably, the company announced the closure of its London-based drug research center, citing the UK’s challenging business environment as a primary factor. This decision is expected to impact its global R&D footprint and may signal a strategic realignment in response to economic pressures. Additionally, Merck and Daiichi Sankyo recently reported positive Phase 2 results for ifinatamab deruxtecan in the treatment of extensive-stage small cell lung cancer. This progress highlights ongoing innovation in the company’s oncology pipeline, offering potential long-term growth opportunities. Meanwhile, Merck has also closed a significant $6 billion notes offering, which analysts suggest could be used to strengthen its financial position or fund future R&D initiatives.

As of late, Merck’s stock has underperformed relative to its peers, with its share price down 14% year-to-date. The decline has been attributed to slowing growth from Keytruda, ongoing challenges with Gardasil sales, and looming patent risks that have cast a shadow over future earnings potential. These factors have contributed to a more cautious outlook among investors. However, recent drug trial successes and capital-raising activities may provide some stability in the near term. Investors should closely monitor how these developments interact with Merck’s broader financial health, including revenue trends, profit margins, and cash flow generation.

In conclusion, Merck’s latest dividend announcement, coupled with recent strategic and operational moves, reflects both challenges and opportunities. Investors should be aware that the ex-dividend date of Sep 15, 2025, is the last day to purchase the stock and qualify for this dividend payment. Any shares acquired after that date will not be eligible to receive the upcoming payout.